Summarising all the above, we provided novel insights into TB-associated inflammation by identifying patient characteristics and findings from the initial clinical evaluation, which were related to delayed reduction in serum CRP levels shortly after anti-TB treatment onset. This evidence concerns the gene CRP and tuberculosis.